All lobbying filings
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. filed a Q4 report for Sarepta Therapeutics, Inc. on January 20, 2026.
Lobbying for Sarepta Therapeutics, Inc.
Filing · LD-2 quarterly report
Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$230,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
2
Lobbying activity
2
Patient Access to Treatments Newborn Screening for Rare Diseases
Scientific Innovation in Healthcare Gene Therapies Rare Diseases Artificial Intelligence and Data Governance